Investing.com -- Ginkgo Bioworks Holdings (NYSE:DNA) stock rose 4.5% in premarket trading Friday after the company announced it has been awarded a contract worth up to $47 million from the Environmental Molecular Sciences Laboratory at Pacific Northwest National Laboratory.
The four-year contract involves co-designing, building, and integrating a High-Throughput Automated Phenotyping Platform to support the Department of Energy’s Microbial Molecular Phenotyping Capability. Ginkgo secured the contract through a competitive procurement process.
The platform will utilize Ginkgo Automation’s Catalyst scheduling software and modular Reconfigurable Automation Carts to automate workflows from media preparation to sample analysis. The system is designed to help PNNL adapt as scientific needs evolve while maintaining high operational uptime.
"Our team is excited to contract and collaborate with PNNL again to build a new capability we believe will expand access to high-quality biological phenotyping at scale," said Will Serber, General Manager of Ginkgo Automation.
The platform aims to increase throughput and reproducibility of phenotyping campaigns across diverse microbes, capture multimodal analytical measurements suitable for AI/ML, and provide a foundation for future instrumentation at PNNL’s Environmental Molecular Sciences Laboratory.
Jason Kelly, CEO of Ginkgo Bioworks, noted that the project aligns with President Trump’s recent AI Action Plan, which called for investment in AI-enabled cloud laboratories to accelerate U.S. scientific innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
